CICC has upheld its forecast for MICROPORT's (00853) 2026 net profit attributable to shareholders at US$74 million while introducing a new projection of US$24 million for 2027. The firm reaffirmed its Outperform rating but reduced the target price by 15% to HK$14.5 based on a DCF valuation, indicating a potential 58% upside.
Key insights from CICC include: - 2025 results aligned with market expectations, with revenue reaching US$1.105 billion, up 6.0% year-over-year (excluding currency effects). The company reported a net profit of US$49 million, reversing from a loss in the prior year, and operating cash flow turned positive at US$69 million for the first time since 2020. - Segment performance varied in 2025, though the overall trend remained positive, with strong contributions from the Global Access platform: 1) Cardiovascular intervention revenue was US$182 million, up 11% excluding currency impact, with new products beyond stents expected to drive further growth. 2) Orthopedics revenue fell 7.5% to US$235 million due to slight overseas declines and challenges in China from procurement policies and operational adjustments; a recovery is anticipated in 2026. 3) CRM revenue held steady at US$230 million, with potential synergies following integration with MicroPort CardioFlow. 4) Structural heart revenue increased 1.3% to US$51 million. 5) Aortic and peripheral vascular revenue grew 12% to US$189 million. 6) Neurovascular revenue rose 3.8% to approximately US$111 million. 7) Surgical robotics revenue surged 114% to US$78 million. - Overseas revenue climbed 15% to US$584 million, accounting for 53% of total revenue. The Global Access platform generated US$164 million, up 78.8%, representing 15% of total revenue and significantly boosting international sales in robotics, structural heart, aortic, peripheral, and neurovascular segments. The platform is estimated to have reached breakeven in 2025. - Cost reduction and asset restructuring efforts continued, with gross margin improving by 1.7 percentage points to 57.4% and operating expense ratio decreasing by 10.3 points to 57.4%. Further margin expansion and expense optimization are expected in 2026, potentially leading to operational profitability. - The integration of MicroPort CardioFlow and CRM in December 2025 eliminated a US$270 million repurchase obligation and is likely to yield cost synergies. Asset disposal gains exceeded US$300 million in 2025, with ongoing efforts to divest non-core assets and optimize structure through sales and investor introductions to enhance liability and cash flow positions. Interest-bearing debt decreased from US$1.84 billion to US$1.55 billion during the year, reflecting improved financial health. - Risks include potential setbacks in M&A integration, slower-than-expected international expansion, and intensified competition.
Comments